CN1389475A - Wolfberry polysaccharide and its prepn. and application - Google Patents
Wolfberry polysaccharide and its prepn. and application Download PDFInfo
- Publication number
- CN1389475A CN1389475A CN 02115382 CN02115382A CN1389475A CN 1389475 A CN1389475 A CN 1389475A CN 02115382 CN02115382 CN 02115382 CN 02115382 A CN02115382 A CN 02115382A CN 1389475 A CN1389475 A CN 1389475A
- Authority
- CN
- China
- Prior art keywords
- lycium barbarum
- molecular weight
- barbarum polysaccharide
- polysaccharide
- ultra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of polyose of lycium chinensis. The composition and proportion of the components of the active polyose that it contains are as follows: molecular weight 100,000-180,000:18,000-80,000:3,000-8,000 and corresponding proportion: 4-20%:8-40%:4-20%. The preparing method is as follows: use of lycium chinensis as raw material, add 8-20 times hot water of 50-100 centigrade to it, then use the high-speed cutter to cut it for 10-40 minutes, then press it, extract the juice pressed from it to high-speedily centrifugate the juice, then use the ultra-filtration membrane which can hold back the molecules whose molecular weight is 5-100,000 to filter the centrifugal juice, then use the ultra-filtration membrane which can hold back the molecules whose molecular weight is 3,000-10,000 to condense the ultra-filtration liquid.
Description
Affiliated technical field
The present invention relates to a kind of lycium barbarum polysaccharide, simultaneously, the invention still further relates to a kind of preparation method of described lycium barbarum polysaccharide and in treatment because the application aspect the disease that causes of immunocompromised.
Background technology
Main active ingredient in the wolfberry fruit is a polyose, and its main effect can improve the immunological competence of body, thereby can be used for the treatment of the disease that lowly causes because of immunological competence, as long-term flu, asthma, cancer etc.Carbohydrate is in the majority with monose and oligosaccharides in the wolfberry fruit, and polysaccharide content is less relatively.In polysaccharide extracting process in the past, have the leaching process of long-time high heat more, as decocting and concentrating, so not only can make the finished product color burn, also make many polysaccharide fragment into oligosaccharides and monose simultaneously.According to the research report, the lycium barbarum polysaccharide of obvious pharmacological action is arranged, its molecular weight is many more than 10,000, and the research at present of matrimony vine monose and oligosaccharides thinks there be not pharmacological action, if must be pure excessively with separation of polysaccharides, then pharmacological action has the phenomenon of obvious reduction.
Summary of the invention
The object of the present invention is to provide a kind of lycium barbarum polysaccharide, its activeconstituents is clear and definite, and is quality controllable, and it is reliable to be used for the treatment of the curative effect of disease that lowly causes because of immunological competence, and almost has no adverse reaction.
Another object of the present invention is to provide this lycium barbarum polysaccharide preparation method, this method technology is simple, the product yield height.
The present invention also aims to provide the application aspect the disease that this lycium barbarum polysaccharide lowly causes because of immunological competence in treatment.
Lycium barbarum polysaccharide provided by the invention, the composition of its contained active polysaccharide composition and ratio are: molecular weight is 100,000～180,000: 10,000～80,000: 0.3 ten thousand～0.8 ten thousand=(4～20%): (8～40%): (4～20%).
The preparation method of lycium barbarum polysaccharide provided by the invention, with the Chinese medicine matrimony vine is raw material, may further comprise the steps: get wolfberry fruit and put in the container, add 8～20 times 50～100 ℃ hot water, sheared 10～40 minutes with high-speed shearing machine, squeezing, pressure expressed juice high speed centrifugation, the centrifugate molecular weight cut-off is 5～100,000 ultrafiltration membrance filter, ultrafiltrated is that 3000～10000 ultra-filtration membrane concentrates with molecular weight cut-off again, lyophilize, promptly.
The inventive method is sheared with hot water, and polysaccharide is dissolved in rapidly in the hot water, avoids pigment Yin Gaowen variation down in the matrimony vine again, makes color burn; Use the ultra-filtration membrane of different molecular weight again, separate and concentrate lyophilize; can avoid high hot leaching process for a long time, make the finished product polysaccharide yield up to more than 80%, outward appearance is good; and whole process of production is simple to operate, carries out large-scale production easily, and cost is low.
Lycium barbarum polysaccharide of the present invention is applied in the disease aspect that treatment lowly causes because of immunological competence, can be mixed with medicament with one or more pharmaceutically acceptable carriers (auxiliary material).
Above-mentioned pharmaceutical excipient is meant the pharmaceutical excipient of pharmaceutical field routine, for example: thinner, vehicle and water etc., weighting agent such as starch, N.F,USP MANNITOL, dextrin, sucrose, lactose, Microcrystalline Cellulose etc.; Tackiness agent such as derivatived cellulose, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerine; Disintegrating agent such as methyl starch sodium, hydroxypropylcellulose, cross-linked carboxymethyl cellulose, agar and sodium bicarbonate; Tensio-active agent such as cetyl alcohol, sodium lauryl sulphate, tween 80 etc.; Absorption carrier such as kaolin and soap clay; Lubricant such as talcum powder, calcium stearate and magnesium, micropowder silica gel and polyoxyethylene glycol etc.Can also in composition, add other assistant agent such as flavouring agent, sweeting agent etc. in addition.
Medicament of the present invention can be applied to the patient who needs this treatment by the mode of oral, rectum or administered parenterally.Be used for when oral, can be made into conventional solid preparation such as tablet, capsule, pulvis, granule etc., make other liquid preparation of liquid preparation such as water or oil-suspending agent such as syrup, mixture, elixir etc.; When being used for administered parenterally, can be made into solution, powder pin, water or the oiliness suspension agent etc. of injection.The preferred form of the present invention is powder pin, injection liquid and tablet, coated tablet, capsule, granule, mixture.
The amount of application of lycium barbarum polysaccharide medicament of the present invention can be according to variations such as the type of route of administration, patient age, body weight, the disease of being treated and severity, and its per daily dose can be 1～500mg/kg body weight, preferred 5～450mg/kg body weight.Can use by one or many.
Lycium barbarum polysaccharide activeconstituents of the present invention is clear and definite, quality controllable, and it is reliable to be used for the treatment of the curative effect of disease that lowly causes because of immunological competence, and almost has no adverse reaction.
The present invention is further illustrated below by embodiment and Pharmacodynamic test of active extract.The preparation of embodiment 1 lycium barbarum polysaccharide
Get wolfberry fruit 1000g, after picking, rinse well with ordinary water, put in the container, the hot water that adds 15 times 80 ℃, sheared 30 minutes squeezing, pressure expressed juice high speed centrifugation with high-speed shearing machine, the centrifugate molecular weight cut-off is 5～100,000 ultrafiltration membrance filter, ultrafiltrated is that 3000～10000 ultra-filtration membrane concentrates with molecular weight cut-off again, lyophilize, promptly.The preparation of embodiment 2 lycium barbarum polysaccharide oral liquids
Embodiment 1 lycium barbarum polysaccharide 50g
Sodium Benzoate 2g
Get embodiment 1 lycium barbarum polysaccharide, add Sodium Benzoate, add the injection water to an amount of, heating for dissolving is put coldly, adds the injection water again to 1000ml, stirs, and with 0.45 μ l filtering with microporous membrane, can is sealed, and 100 ℃, sterilizes in 30 minutes, promptly.The preparation of embodiment 3 lycium barbarum polysaccharide powder pins
Embodiment 1 lycium barbarum polysaccharide 100g
N.F,USP MANNITOL 50g
Get lycium barbarum polysaccharide, add water to N.F,USP MANNITOL, add the injection water to an amount of, heating for dissolving is put coldly, adds the injection water again to 1000ml, stirs, with 0.22 μ l filtering with microporous membrane, be sub-packed in the cillin bottle, and lyophilize, gland seals, promptly.The preparation of embodiment 4 lycium barbarum polysaccharide injection liquids
Embodiment 1 lycium barbarum polysaccharide 100g
Tween-80 1ml
Water for injection adds to 1000ml
Get embodiment 1 lycium barbarum polysaccharide,, transfer pH to 6～7 with 1% sodium hydroxide solution again, add the 1ml tween-80, add water for injection, leave standstill, with the filtering with microporous membrane of 0.22 μ m, embedding, flowing steam sterilization, promptly to 1000ml with the dissolving of 900ml water for injection.The capsular preparation of embodiment 5 lycium barbarum polysaccharides
Embodiment 1 lycium barbarum polysaccharide 500g
Dextrin 425g
Xylo-Mucine 60g
Magnesium Stearate 15g
Get embodiment 1 lycium barbarum polysaccharide, dextrin, Xylo-Mucine, Magnesium Stearate and mix, cross 80 mesh sieves,,, irritate in capsule, promptly with whole of 60 mesh sieves with dry granulation mechanism grain.
Above embodiment is only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
The present invention is to provide natural drug--the lycium barbarum polysaccharide and the medicament thereof of the disease that a kind of novel treatment lowly causes because of immunological competence, for proving its effect and security, the lycium barbarum polysaccharide for preparing by the method that provides in the foregoing description 1 is provided the inventor, the toxicity and the pharmacodynamic experiment that have carried out, result of study is as follows:
One, Pharmacodynamic test of active extract
For observing the effect of embodiment 1 lycium barbarum polysaccharide (being designated hereinafter simply as LBP) as enhance immunity function and antitumor adjuvant therapy medicaments, strengthening vital QI to eliminate pathogenic factors, efficacy enhancing and toxicity reducing test have been carried out in this test.Mouse is all in the 2nd day intravenous administration in inoculation back, continuous 10 days, observe various performances, tumor growth and the death condition of mouse, 1 day execution lotus solid tumor mouse after the drug withdrawal, tumour inhibiting rate, the organ coefficient of observing medicine reach immune influence, study LBP simultaneously whether Cy is had synergism, whether Cy immunocompromised mouse is had detoxification, and carry out the drug effect comparison of iv injection or ig administration, the result shows:
1. 25,50,100mg/kg has restraining effect to the growth of tumor of HepS, is respectively 36.6,48.7,61.6%, the inhibiting rate of oral 100mg/kg is 40.2%; S180 is also had stronger restraining effect, and 100mg/kg can obviously prolong the life of ACE ascites carcinoma mouse.Prompting LBP has stronger antitumor action, and the iv administering effect is better than the ig administration.
2. can obviously improve the WBC number of tumor-bearing mice, rate of rise can be greater than 200%, to different knurl strains with the dosage correlation more complicated; LBP can improve the HepS macrophage phagocytosis of mice, improve lymphocyte transformation rate and NK cell activity; Obviously improve IL-2 and TNF-alpha levels in the serum.Show LBP and the effect that improves immunologic function, but enhancing body is to the lethal effect of tumour.
3. share with Cy and can obviously improve tumour inhibiting rate, reduce the animal dead rate, to the animal of immunocompromised due to chemotherapy, the effect that has tangible rising WBC to improve immunologic function increases spleen and thymus index.Show that this product and chemotherapeutics have share tangible efficacy enhancing and toxicity reducing effect.
The stronger antitumor action of LBP tool significantly improves immunologic function in sum, with the chemotherapy drug combination tangible efficacy enhancing and toxicity reducing effect is arranged, and prompting LBP act as antitumor adjuvant therapy medicaments should good prospect.
Two, acute toxicity test
Under domesticated dog anesthesia (vetanarcol i.v30mg/kg) state, large and small two dosage of intravenous injection LBP (20,100mg/kg crude drug), cumulative volume 5ml/kg, to before the medicine with administration after blood pressure (SBP, DBP, BP), respiratory rate, amplitude, body temperature, heart rate, electrocardiogram(ECG (P, QRS, ST, T ripple interval, the amplitude) parameter measured, have no significant change.Large, medium and small three the dosage groups of LBP (500,250,50mg/kg crude drug three dosage), press 0.1ml/10g body weight mouse iv injection, behind the medicine 30 minutes, to spontaneous activity number of times in the mouse 10 minutes, to mouse peritoneal injection 45mg/kg vetanarcol, the length of one's sleep of animal and physiological saline control group be no difference of science of statistics relatively all.Show that LBP does not all have obvious detrimentally affect to nerve, breathing and cardiovascular systems under corresponding dosage.
Three, long term toxicity test
1, rat long term toxicity test: 160 of Sprague-Dawley rats, divide high dose group (500mg/kg), middle dosage group (160mg extract/kg), low dose group (50mg extract/kg) and 5% glucose injection control group, 40 of every treated animals, male and female half and half.Route of administration is an abdominal injection, and once a day, administration is 6 days weekly, and the medication cycle was 26 weeks.
The result shows, in 26 weeks of LBP intraperitoneal injection, the behavioral activity of rat, fur color and luster and ight soil all belong to normally.Food ration is not found the significantly ANOMALOUS VARIATIONS relevant with drug effect.The body weight gain of high, medium and low dosage treated animal is compared no significant difference with control group.Main organ weights and coefficient thereof and control group be unknown significance difference relatively.Hematology and blood biochemical are learned experiment and are shown, every index that high, medium and low dosage group rat blood is detected and control group are not relatively seen except that the dosage group WBC of senior middle school raises obviously because the ANOMALOUS VARIATIONS of drug-induced.The pathological section result shows that each period, each treated animal lungs all had the minority animal inflammatory reaction to occur, and the minority animal livers cell infiltration occurs and becomes with slight fat, but does not relatively have difference with the blank group.Under this test conditions, 26 weeks of LBPi.v. administration the non-toxic to the SD rat be 500mg/kg.
2, Beagle dog long term toxicity test: 32 of Beagle dogs, test are divided a LBP high dose group (250mg extract/kg), middle dosage group (80mg extract/kg), low dose group (25mg extract/kg) and blank group (5% glucose injection).High, medium and low dosage group and control group, route of administration are intravenous injection, and once a day, 6 times weekly, the medication cycle was 26 weeks.
The result shows, intravenous injection LBP13 week, 26 week the back to senior middle school's dosage group WBC in the routine blood test of dog apparently higher than the blank group, but within normal range; Serum biochemistry, routine urinalysis and food ration etc. are not all found the significantly ANOMALOUS VARIATIONS relevant with drug effect.All are normal after administration for the activity situation of animal.Compare with control group, the dog body weight of each administration group and body weight gain normal and in week no significant difference.The every index of dog electrocardiogram(ECG is normal.The tissue slice inspection shows, examined at all to there is no tangible pathological change in the internal organs.Under this test conditions, 26 weeks of LBPi.v. administration the non-toxic to dog be 250mg/kg.
Claims (3)
1, a kind of lycium barbarum polysaccharide, it is characterized in that the composition of contained active polysaccharide composition and ratio are: molecular weight is 100,000～180,000: 10,000～80,000: 0.3 ten thousand～0.8 ten thousand=(4～20%): (8～40%): (4～20%).
2, the preparation method of the described lycium barbarum polysaccharide of claim 1, it is characterized in that with the Chinese medicine matrimony vine be raw material, may further comprise the steps: get wolfberry fruit and put in the container, add 8～20 times 50～100 ℃ hot water, sheared 10～40 minutes with high-speed shearing machine, squeezing, pressure expressed juice high speed centrifugation, the centrifugate molecular weight cut-off is 5～100,000 ultrafiltration membrance filter, ultrafiltrated is that 3000～10000 ultra-filtration membrane concentrates with molecular weight cut-off again, lyophilize, promptly.
3, the described lycium barbarum polysaccharide of claim 1 is being treated because the application aspect the disease that immunocompromised causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021153825A CN1169839C (en) | 2002-06-14 | 2002-06-14 | Wolfberry polysaccharide and its prepn. and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021153825A CN1169839C (en) | 2002-06-14 | 2002-06-14 | Wolfberry polysaccharide and its prepn. and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1389475A true CN1389475A (en) | 2003-01-08 |
| CN1169839C CN1169839C (en) | 2004-10-06 |
Family
ID=4743607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021153825A Expired - Fee Related CN1169839C (en) | 2002-06-14 | 2002-06-14 | Wolfberry polysaccharide and its prepn. and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1169839C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444897C (en) * | 2006-03-06 | 2008-12-24 | 南京凯瑞尔纳米生物技术有限公司 | Nano complex eye drops containing liposoluble compound drug and its preparing method |
| CN101006842B (en) * | 2006-01-24 | 2011-07-13 | 抚顺正航食品有限公司 | A Chinese herbal polysaccharide cake |
| CN102942635A (en) * | 2012-11-22 | 2013-02-27 | 天津科技大学 | Extraction method of high cell apoptosis induction active lycium barbarum polysaccharide |
| CN103772522A (en) * | 2014-01-13 | 2014-05-07 | 东北林业大学 | Polymer emulsifying shearing extraction method for auricularia auricular polysaccharide |
| EP2778177A4 (en) * | 2011-11-07 | 2015-07-29 | Shenyang Kesi High Technology Co Ltd | Method for extracting polysaccharides from higher plants and fungi through microwave chemical treatment |
| CN105250988A (en) * | 2015-11-06 | 2016-01-20 | 安徽生物肽产业研究院有限公司 | Compound donkey-hide gelatin small peptide composition for nourishing blood and beautifying skin |
| CN106478836A (en) * | 2016-11-24 | 2017-03-08 | 中国科学院兰州化学物理研究所 | A kind of preparation method of LBP-X |
| CN109608557A (en) * | 2019-01-10 | 2019-04-12 | 华东理工大学 | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method |
-
2002
- 2002-06-14 CN CNB021153825A patent/CN1169839C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101006842B (en) * | 2006-01-24 | 2011-07-13 | 抚顺正航食品有限公司 | A Chinese herbal polysaccharide cake |
| CN100444897C (en) * | 2006-03-06 | 2008-12-24 | 南京凯瑞尔纳米生物技术有限公司 | Nano complex eye drops containing liposoluble compound drug and its preparing method |
| EP2778177A4 (en) * | 2011-11-07 | 2015-07-29 | Shenyang Kesi High Technology Co Ltd | Method for extracting polysaccharides from higher plants and fungi through microwave chemical treatment |
| CN102942635A (en) * | 2012-11-22 | 2013-02-27 | 天津科技大学 | Extraction method of high cell apoptosis induction active lycium barbarum polysaccharide |
| CN102942635B (en) * | 2012-11-22 | 2015-01-28 | 天津科技大学 | Extraction method of high cell apoptosis induction active lycium barbarum polysaccharide |
| CN103772522A (en) * | 2014-01-13 | 2014-05-07 | 东北林业大学 | Polymer emulsifying shearing extraction method for auricularia auricular polysaccharide |
| CN105250988A (en) * | 2015-11-06 | 2016-01-20 | 安徽生物肽产业研究院有限公司 | Compound donkey-hide gelatin small peptide composition for nourishing blood and beautifying skin |
| CN106478836A (en) * | 2016-11-24 | 2017-03-08 | 中国科学院兰州化学物理研究所 | A kind of preparation method of LBP-X |
| CN106478836B (en) * | 2016-11-24 | 2019-04-26 | 中国科学院兰州化学物理研究所 | A kind of preparation method of polysaccharides |
| CN109608557A (en) * | 2019-01-10 | 2019-04-12 | 华东理工大学 | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1169839C (en) | 2004-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1448215B1 (en) | Use of laminarin in the treatment of cancer | |
| CN1985846A (en) | Use of brown algae polyose sulfate in preparing medicine fortreating cardic and cerebral vascular diseases | |
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| JPS60214741A (en) | Hypoglycemic agent | |
| CN1169839C (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN105796861B (en) | Application of phillyrin derivative and phillyrin-phillygenin composition in preparation of medicine for improving immune function | |
| CN106074493A (en) | The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract | |
| CN101053574A (en) | Medicinal composition containing chitoser ester and preparation method and application thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN101703497B (en) | Application of Chlorogenic acid in preparing drug having protection and restoration functions on spleen hematopoietic stem cell injuries | |
| CN113069510A (en) | Composition for enhancing immunity and preparation method and application thereof | |
| CN110856744B (en) | New application of dendrobe polypeptide | |
| CN1401365A (en) | Chinese health medicine | |
| CN101212963B (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN101099754A (en) | Preparation method and application for pedunculoside II | |
| CN1094762C (en) | Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof | |
| CN113521262A (en) | Lysozyme preparation with anti-inflammatory effect | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| JP2021512998A (en) | Isolated white chili polysaccharide and its uses | |
| CN1854148B (en) | Astragalus total heteroside extract and its production | |
| JPH0245501A (en) | Chikusetsu ginseng polysaccharide and use thereof | |
| EP0970968A1 (en) | Pharmacologically active substance | |
| CN100482245C (en) | Medicine composition contg. isatis root and scutellariae glucoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |